CampbellNRBurgessEChoiBCK. Methods and overview of the Canadian recommendations. CMAJ1999;160(9 suppl):S1-S6.
2.
LeungAANerenbergKDaskalopoulouSS. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol2016;32:569-88.
3.
JoffersMFalaschettiEGillespieC. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open2013;3(8):e003423.
4.
PadwalRSBienekAMcAlisterFACampbellNR.Epidemiology of hypertension in Canada: an update. Can J Cardiol2016;32:687-94.
5.
Chisholm-BurnsMAKim LeeJSpiveyCA. US pharmacists’ effect as a team member on patient care: systematic review and meta-analyses. Med Care2010;48:923-33.
6.
SantschiVChioleroABurnandA. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med2011;171;1441-53.
7.
SantschiVChioleroAParadisG. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta analysis of randomized controlled trials. Diabetes Care2012;35:2706-17.
8.
SantschiVChioleroAColosimoAL. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc2014;3:e000718.
9.
TsuyukiRHouleSCharroisT. A randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION). Circulation2015;132:93-100.
10.
PojskicNJacksonMMalekACiminoS.Impact of community pharmacist interventions in hypertension management on patient outcomes: a randomized controlled trial. Can Pharm J (Ott)2014;147:S17.
11.
TsuyukiRTAl HamarnehYNJonesCAHemmelgarnBR.Effectiveness of community pharmacist prescribing and care on cardiovascular risk reduction: randomized controlled RxEACH trial. J Am Coll Cardiol2016;67(24):2846-54. doi:10.1016/j.jacc.2016.03.528
12.
HouleSKDTsuyukiRTCampbellNRC. The Canadian Hypertension Education Program (CHEP) 2011 guidelines for pharmacists. Can Pharm J (Ott)2011;144:295-304.
13.
HouleSKDPadwalRTsuyukiRT. The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2013;146:146-50.
14.
HouleSKDPadwalRPoirierLTsuyukiRT. The 2014 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2014;147:203-8.
15.
HouleSKDPadwalRPoirierLTsuyukiRT. The 2015 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2015;148:180-6.
16.
DaskalopoulouSSRabiDMZarnkeKB. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol2015;31:549-68.
17.
MyersMGGodwinMDawesM. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ2011;342:d286.
18.
MyersMGValdiviesoMKissA.Consistent relationship between automated office blood pressure recorded in different settings. Blood Press Monit2009;14:108-11.
19.
MyersMGValdiviesoMKissA.Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens2009;27:280-6.
20.
WrightJTJrWilliamsonJDWheltonPK. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med2015;373:2103-16.
21.
BrouwersMCKhoMEBrowmanGP. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ2010;182:E839-42.
22.
MyersMG.A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. J Hypertens2010;28:703-8.
23.
MyersMG.The great myth of office blood pressure measurement. J Hypertens2012;30:1894-8.
24.
MyersMG.Eliminating the human factor in office blood pressure measurement. J Clin Hypertens (Greenwich)2014;16:541-2.
25.
MyersMGGodwinM.Automated measurement of blood pressure in routine clinical practice. J Clin Hypertens (Greenwich)2007;9:267-70.
26.
MyersMGGodwinMDawesM. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Fam Pract2012;29:376-82.
27.
GreiverMWhiteDKaplanDM. Where should automated blood pressure measurements be taken? Pilot RCT of BpTRU measurements taken in private or nonprivate areas of a primary care office. Blood Press Monit2012;17:137-8.
28.
MyersMGGodwinMDawesM. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension2010;55:195-200.
29.
MyersMGOhPIReevesRAJoynerCD.Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens1995;8:591-7.
30.
ArmstrongDMatangiMBrouillardDMyersMG.Automated office blood pressure—being alone and not location is what matters most. Blood Press Monit2015;20:204-8.
31.
PadwalRSTownsendRRTrudeauL. Comparison of an in-pharmacy automated blood pressure kiosk to daytime ambulatory blood pressure in hypertensive subjects. J Am Soc Hypertens2015;9:123-9.
32.
ChambersLWKaczorowskiJO’RiellyS. Comparison of blood pressure measurements using an automated blood pressure device in community pharmacies and family physicians’ offices: a randomized controlled trial. CMAJ Open2013;1:E37-42.
33.
AndreadisEAAgaliotisGDAngelopoulosET. Automated office blood pressure and 24-h ambulatory measurements are equally associated with left ventricular mass index. Am J Hypertens2011;24:661-6.
34.
AndreadisEAAgaliotisGDAngelopoulosET. Automated office blood pressure is associated with urine albumin excretion in hypertensive subjects. Am J Hypertens2012;25:969-73.
35.
CampbellNRMcKayDWConradsonH. Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima-medial thickness in male firefighters. J Hum Hypertens2007;21:588-90.
36.
MyersMGKaczorowskiJPatersonJM. Thresholds for diagnosing hypertension based on automated office blood pressure measurements and cardiovascular risk. Hypertension2015;66:489-95.
37.
SidhuDNauglerC.Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172:1707-10.
38.
DoranBGuoYXuJ. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation2014;130:546-53.
39.
LangstedAFreibergJJNordestgaardBG.Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation2008;118: 2047-56.
40.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [erratum in Lancet 1999;354:602]. Lancet1998;352:837-53.
41.
BansalSBuringJERifaiN. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA2007;298:309-16.
42.
Emerging Risk Factors Collaboration, Di AngelantonioESarwarN. Major lipids, apolipoproteins, and risk of vascular disease. JAMA2009;302:1993-2000.
43.
NordestgaardBGVarboA.Triglycerides and cardiovascular disease. Lancet2014;384:626-35.
44.
AldasouqiSSheikhAKlostermanP. Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. Diabetes Care2011;34:e52.
45.
de VriesMKlopBCastro CabezasM. The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice—point of view. Atherosclerosis2014;234:473-5.
46.
KheraAVMoraS.Fasting for lipid testing: is it worth the trouble?Arch Intern Med2012;172:1710-2.
47.
AburtoNJHansonSGutierrezH. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ2013;346:f1378.
48.
EttehadDEmdinCAKiranJ. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta analysis. Lancet2016;387:957-67.
49.
XieXAtkinsELvJ. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet2016;387:435-43.
50.
PepineCJHandbergEMCooper-DeHoffRM. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilTrandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290:2805-16.
51.
DargieHJFordIFoxKM.Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J1996;17:104-12.
52.
RehnqvistNHjemdahlPBillingE. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J1996;17:76-81.
53.
AndalibAAkhtariSRigalR. Determinants of masked hypertension in hypertensive patients treated in a primary care setting. Intern Med J2012;42:260-6.
OhkuboTKikuyaMMetokiH. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol2005;46:508-15.
56.
GroverSALowensteynIJosephL. Discussing coronary risk with patients to improve blood pressure treatment: secondary results from the CHECK-UP study. J Gen Intern Med2009;24:33-9.
57.
GeeMEBienekAMcAlisterFA. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol2012;28:375-82.
58.
SteadLFHartmann-BoyceJPereraRLancasterT.Telephone counselling for smoking cessation. Cochrane Database Syst Rev2013:CD002850.
59.
CahillKLancasterT.Workplace interventions for smoking cessation. Cochrane Database Syst Rev2014:CD003440.
